About these reports
Using data derived from Beacon as of 11th of January 2023, the following series provides analysis of the existing TPD landscape, an overview of what happened in 2022, and a look at what the future might bring.
The three part analysis is split into:
- TPD Highlights from 2022 – Regulatory announcements, drugs that entered the clinic, collaborations and more
- The Current Landscape Overview – Including therapeutic classes, targets and trials
- The Bivalent Degrader Landscape/The Future of TPD – Development status and developers in the bivalent degrader space, looking beyond degradation and much more
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
How the most complete TPD database can help you
What we cover
Beacon Targeted Protein Degradation (TPD) covers trial and drug records for clinical, preclinical, approved and discontinued therapeutics involved in targeted protein degradation. The database covers:
- Bivalent Degraders
- Monovalent Degraders
- Proteasome Inhibitors
- DUB Inhibitors
- E1/E2/E3 Modulators
- Other comparable modalities
How Beacon TPD works
Search the trial and drug landscape by target, ligands and ligases alongside other search criteria to instantly extract the data points you need to conduct more complex analysis.